Novel agents in development for multidrug-resistant Gram-negative infections: potential new options facing multiple challenges
Sign Up to like & getrecommendations! Published in 2022 at "Current Opinion in Infectious Diseases"
DOI: 10.1097/qco.0000000000000885
Abstract: Purpose of review To review novel antiinfective agents in development for multidrug-resistant (MDR) Gram-negative bacterial infections. Recent findings Four novel agents are in various phases of development (tebipenem, durlobactam-sulbactam, cefepime-taniborbactam, and xeruborbactam). Tebpipenem is an… read more here.
Keywords: development multidrug; development; agents development; multidrug resistant ... See more keywords
LncRNA DANCR accelerates the development of multidrug resistance of gastric cancer.
Sign Up to like & getrecommendations! Published in 2019 at "European review for medical and pharmacological sciences"
DOI: 10.26355/eurrev_201904_17554
Abstract: OBJECTIVE The development of multidrug resistance (MDR) is a key issue for tumor recurrence and metastasis, leading to treatment failure of gastric cancer (GC). Long non-coding RNA (lncRNA) DANCR has been shown to be highly… read more here.
Keywords: development multidrug; ddp; dancr; bgc823 ... See more keywords